Gladius Capital Management LP Buys 1,010 Shares of Orthofix Medical Inc. (NASDAQ:OFIX)

Gladius Capital Management LP lifted its stake in Orthofix Medical Inc. (NASDAQ:OFIX) by 55.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,841 shares of the medical device company’s stock after buying an additional 1,010 shares during the period. Gladius Capital Management LP’s holdings in Orthofix Medical were worth $38,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in OFIX. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Orthofix Medical by 30.4% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,516 shares of the medical device company’s stock worth $101,000 after acquiring an additional 1,752 shares during the period. State Board of Administration of Florida Retirement System bought a new position in Orthofix Medical during the third quarter worth about $130,000. Teza Capital Management LLC acquired a new stake in Orthofix Medical during the third quarter valued at approximately $133,000. Arizona State Retirement System bought a new stake in shares of Orthofix Medical in the 4th quarter valued at approximately $138,000. Finally, Versor Investments LP acquired a new position in shares of Orthofix Medical in the 3rd quarter worth approximately $186,000. 89.76% of the stock is owned by institutional investors and hedge funds.

Orthofix Medical Trading Down 2.8 %

Orthofix Medical stock traded down $0.41 during mid-day trading on Thursday, hitting $14.49. The stock had a trading volume of 380,003 shares, compared to its average volume of 409,470. The stock has a market capitalization of $542.07 million, a PE ratio of -3.50 and a beta of 1.06. Orthofix Medical Inc. has a 12 month low of $9.57 and a 12 month high of $21.60. The company has a current ratio of 2.54, a quick ratio of 1.20 and a debt-to-equity ratio of 0.19. The stock has a 50-day simple moving average of $13.69 and a two-hundred day simple moving average of $13.04.

Orthofix Medical (NASDAQ:OFIX) last issued its earnings results on Tuesday, March 5th. The medical device company reported ($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.60) by $0.01. The company had revenue of $200.42 million for the quarter. Orthofix Medical had a negative net margin of 20.28% and a negative return on equity of 10.63%. As a group, sell-side analysts forecast that Orthofix Medical Inc. will post -1.51 EPS for the current year.

Wall Street Analysts Forecast Growth

OFIX has been the topic of a number of analyst reports. Roth Capital upgraded Orthofix Medical from a “neutral” rating to a “buy” rating in a research report on Wednesday. Roth Mkm upgraded shares of Orthofix Medical from a “neutral” rating to a “buy” rating and raised their price objective for the company from $15.00 to $20.00 in a research report on Wednesday. StockNews.com upgraded shares of Orthofix Medical from a “sell” rating to a “hold” rating in a research report on Wednesday. Finally, JMP Securities reissued a “market perform” rating on shares of Orthofix Medical in a research note on Monday, April 22nd. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $18.00.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.